Drug Trial Radar · NCT03875079
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Jun 24, 2019
Primary completion
Jul 14, 2022
Study completion Jul 14, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1. and 1.2) and two expansion parts (Parts II and III). Part II will start once all participants in Cohort 1.1 have completed the observation period. Part III will start once all participants in Cohorts 1.1 and 1.2 have completed the observation period.
Conditions
- Metastatic Melanoma
Interventions
RO6874281Drug
Part I Safety Run in: Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study. Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study. Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome). Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule.
PembrolizumabDrug
Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks). Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome) Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with adverse eventsTime frame: Baseline to end of study (approximately 24 months)
Locations
23 sites in 7 countries. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut
University of Iowa
Iowa City, Iowa
Beth Israel Deaconess Med Ctr
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Melanoma Institute Australia
North Sydney, New South Wales, Australia
Peter Maccallum Cancer Institute; Clinical Trial Unit
Melbourne, Victoria, Australia
UZ Antwerpen
Edegem, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Hopital Claude Huriez; Sce Dermatologie
Lille, France
Hôpital de la Timone; Dermatologie
Marseille, France
Centre Eugene Marquis; Service d'oncologie
Rennes, France
Institut Gustave Roussy; Dermatologie
Villejuif, France
Russian Oncology Research Center n.a. N.N. Blokhin
Moscow, Russia
P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept
Moscow, Russia
FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
Saint Petersburg, Russia
Main Military Clinical Hospital named after N.N. Burdenko
Moscow, Moscow Oblast, Russia
Hospital Universitari Vall d'Hebron; Oncology
Barcelona, BARCELONA, Spain
Hospital Clínic i Provincial; Servicio de Oncología
Barcelona, BARCELONA, Spain
Clinica Universidad de Navarra Madrid; Servicio de Oncología
Madrid, Madrid, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, Madrid, Spain
Clinica Universitaria de Navarra; Servicio de Oncologia
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.